Drug resistance test shows encouraging results.
Researchers continue to find evidence that the combination of lopinavir/ritonavir (Kaletra) provides prolonged potency while avoiding drug resistance. The Kaletra findings come on the heels of another study that found a high rate of drug resistance among HIV patients with measurable levels of virus in their blood.
D004338:Drug Combinations; D004352:Drug Resistance, Microbial / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir